<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5101">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173055</url>
  </required_header>
  <id_info>
    <org_study_id>MD-SAV-09</org_study_id>
    <nct_id>NCT01173055</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia</brief_title>
  <official_title>A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia is a condition that includes pain, tenderness, stiff muscle, and fatigue.
      Researchers want to find out if &quot;a drug&quot; called milnacipran can help people with
      fibromyalgia. milnacipran (Savella) is approved by the FDA for the management of
      fibromyalgia. In this study, milnacipran will be given to find out more about how it affects
      pain and thinking in people with fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the effect of milnacipran on pain processing in
      patients with fibromyalgia and to assess the correlation between this effect and neural
      activation patterns during functional Magnetic Resonance Imaging (fMRI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pain Threshold at Baseline</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome parameter is the medium pressure pain threshold at pre-treatment baseline (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale). Measured in kg/cm^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain Threshold From Baseline to Week 6 of Treatment.</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome parameter is the change in medium pressure pain threshold from baseline to week 6 of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain Threshold From Baseline to Week 9 of Treatment</measure>
    <time_frame>Week 9</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome parameter is the change in medium pressure pain threshold from baseline to end of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain Threshold From Baseline to End of Treatment.</measure>
    <time_frame>Week 0 - Week 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome parameter is the change in medium pressure pain threshold (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffuse Noxious Inhibitory Control (DNIC) Effect at Baseline.</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to Week 6 of Treatment.</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to Week 9 of Treatment.</measure>
    <time_frame>Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.</measure>
    <time_frame>Week 0 - Week 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Tolerance at Baseline</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome parameter is the pressure pain tolerance (maximum tolerated pressure) at pre-treatment baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Tolerance From Baseline to Week 6 of Treatment</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Tolerance From Baseline to Week 9 of Treatment</measure>
    <time_frame>Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Tolerance From Baseline to End of Treatment</measure>
    <time_frame>Week 0 -Week 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome parameter is the change in pressure pain tolerance (maximum tolerated pressure) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to End of Treatment</measure>
    <time_frame>Week 0 to Week 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to Week 6 of Treatment</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to Week 9 of Treatment</measure>
    <time_frame>Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to Week 15 of Treatment</measure>
    <time_frame>Week 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Descending Pain Modulation From Baseline to End of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</measure>
    <time_frame>Week 0 - Week 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Descending Pain Modulation From Baseline to Week 6 of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Descending Pain Modulation From Baseline to Week 9 of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</measure>
    <time_frame>Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Descending Pain Modulation From Baseline to Week 15 of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</measure>
    <time_frame>Week 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Activation Patterns During N-back Procedure From Baseline to End of Treatment.</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Activation Patterns During N-back Procedure From Baseline to Week 6 of Treatment.</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Activation Patterns During N-back Procedure From Baseline to Week 9 of Treatment.</measure>
    <time_frame>Week 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI Activation Patterns During N-back Procedure From Baseline to Week 15 of Treatment.</measure>
    <time_frame>Week 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Milnacipran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo will be given orally twice daily in tablet form at different times during the course of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>milnacipran</intervention_name>
    <description>Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
    <arm_group_label>Milnacipran</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given orally twice daily in tablet form at different times during the course of the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo/sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You may be eligible to take part in this study if the following are true:

               -  You are between the age of 18 and 70 years

               -  If you are female

               -  If you are right handed

               -  You have a diagnosis of fibromyalgia for at least 3 months, as defined by the
                  American College of Rheumatology 1990 Criteria

               -  You are willing to stop taking certain medicines that you may be taking on a
                  regular basis. The researchers will discuss these medications with you in detail

        Exclusion Criteria:

          -  You may not be eligible take part in this study if any of the following are true for
             you:

               -  You have problems with your heart or cardiovascular system

               -  You have problems with your liver or kidneys

               -  You have an autoimmune disease, or a whole-body infection like HIV or hepatitis

               -  You have cancer

               -  You are pregnant or breastfeeding

               -  You abuse drugs or alcohol

               -  You have suicidal thoughts or wishes

               -  You have taken milnacipran or another study drug within the last 30 days

               -  You have a medical problem not listed here that would make it unsafe for you to
                  take part in the study

               -  The research team feels that you will be unable to complete all phases of the
                  study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Clauw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan, Chronic Pain and Fatigue Research Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 3, 2015</lastchanged_date>
  <firstreceived_date>July 29, 2010</firstreceived_date>
  <firstreceived_results_date>August 5, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Daniel Clauw, MD</investigator_full_name>
    <investigator_title>Daniel Clauw, Professor of Anesthesiology, University of Michigan</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants enrolled in the study received placebo for 1 week (Day -7 to 0) then began the double blinded treatment sequence.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Milnacipran First, Then Placebo</title>
          <description>Milnacipran then placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Milnacipran First, Then Placebo: Period 1 (Day 1-49); Milnacipran 12.5mg by mouth (PO) Day 1; 12.5mg twice daily (BID) Day 2 to 3; 25mg BID Day 4 to 7; 50mg BID Day 8-14; 100mg BID Day 15-42 followed by taper Day 43-49 and a 14 day washout period. Then, placebo matching study treatment in similar pattern to Period 1 was administered beginning Period 2 (Day 64-112).</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Milnacipran</title>
          <description>Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo First, Then Milnacipran: Period 1 (Day 1-49); Placebo matching study treatment was administered beginning Period 1 (Day 1-49) and a 14 day washout period. Then, Milnacipran Period 2 (Day 64-112); Milnacipran 12.5mg Day 62; 12.5mg twice daily (BID) Day 65 to 66; 25mg BID Day 67 to 70; 50mg BID Day 71-77; 100mg BID Day 78-105 followed by taper Day 106-112.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - Day 1 to 49</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Placebo Washout Period - Day 50 to 63</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 - Day 64 to 112</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The milnacipran then placebo arm was reduced from eight to six participants for the analysis due to tolerating a dose of Milnacipran less than 200mg/day. This was done to be consistent with the dosing of all other participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Milnacipran First, Then Placebo</title>
          <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Milnacipran</title>
          <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Fibromyalgia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46.83" spread="9.83"/>
                <measurement group_id="B2" value="36.67" spread="8.64"/>
                <measurement group_id="B3" value="40.73" spread="10.187"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Threshold at Baseline</title>
        <description>The primary outcome parameter is the medium pressure pain threshold at pre-treatment baseline (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale). Measured in kg/cm^2.</description>
        <time_frame>Week 0</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Threshold at Baseline</title>
            <description>The primary outcome parameter is the medium pressure pain threshold at pre-treatment baseline (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale). Measured in kg/cm^2.</description>
            <units>kg/cm^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.7333" spread=".83166"/>
                  <measurement group_id="O2" value="2.583" spread=".84339"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Threshold From Baseline to Week 6 of Treatment.</title>
        <description>The primary outcome parameter is the change in medium pressure pain threshold from baseline to week 6 of treatment.</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Threshold From Baseline to Week 9 of Treatment</title>
        <description>The primary outcome parameter is the change in medium pressure pain threshold from baseline to end of treatment.</description>
        <time_frame>Week 9</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Threshold From Baseline to End of Treatment.</title>
        <description>The primary outcome parameter is the change in medium pressure pain threshold (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome.</description>
        <time_frame>Week 0 - Week 15</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Pain Threshold From Baseline to End of Treatment.</title>
            <description>The primary outcome parameter is the change in medium pressure pain threshold (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome.</description>
            <units>kg/cm^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre-Treatment (Week 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.7333" spread=".83166"/>
                  <measurement group_id="O2" value="2.583" spread=".84339"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Treatment (Week 15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.650" spread="1.05982"/>
                  <measurement group_id="O2" value="2.70" spread=".99642"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diffuse Noxious Inhibitory Control (DNIC) Effect at Baseline.</title>
        <description>0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome.</description>
        <time_frame>Week 0</time_frame>
        <safety_issue>No</safety_issue>
        <population>One participant did not complete this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Diffuse Noxious Inhibitory Control (DNIC) Effect at Baseline.</title>
            <description>0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.134" spread="17.51978"/>
                  <measurement group_id="O2" value="12.0240" spread="20.80824"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to Week 6 of Treatment.</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to Week 9 of Treatment.</title>
        <time_frame>Week 9</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.</title>
        <description>0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome.</description>
        <time_frame>Week 0 - Week 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>On participant did not complete this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.</title>
            <description>0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre-Treatment (Week 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.134" spread="17.51978"/>
                  <measurement group_id="O2" value="12.0240" spread="20.80824"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Treatment (Week 15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0355" spread="17.16822"/>
                  <measurement group_id="O2" value="8.50" spread="19.6678"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Tolerance at Baseline</title>
        <description>The primary outcome parameter is the pressure pain tolerance (maximum tolerated pressure) at pre-treatment baseline.</description>
        <time_frame>Week 0</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Tolerance at Baseline</title>
            <description>The primary outcome parameter is the pressure pain tolerance (maximum tolerated pressure) at pre-treatment baseline.</description>
            <units>kg/cm^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.2667" spread="1.39983"/>
                  <measurement group_id="O2" value="3.80" spread="1.17716"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Tolerance From Baseline to Week 6 of Treatment</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Tolerance From Baseline to Week 9 of Treatment</title>
        <time_frame>Week 9</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Tolerance From Baseline to End of Treatment</title>
        <description>The primary outcome parameter is the change in pressure pain tolerance (maximum tolerated pressure) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome.</description>
        <time_frame>Week 0 -Week 15</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
milnacipran, then placebo: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Placebo, then milnacipran: Milnacipran and placebo will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Pain Tolerance From Baseline to End of Treatment</title>
            <description>The primary outcome parameter is the change in pressure pain tolerance (maximum tolerated pressure) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome.</description>
            <units>kg/cm^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pre-Treatment (Week 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.2667" spread="1.39983"/>
                  <measurement group_id="O2" value="3.80" spread="1.17716"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Treatment (Week 15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8667" spread="1.43261"/>
                  <measurement group_id="O2" value="3.8667" spread="1.20218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to End of Treatment</title>
        <time_frame>Week 0 to Week 15</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to Week 6 of Treatment</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to Week 9 of Treatment</title>
        <time_frame>Week 9</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to Week 15 of Treatment</title>
        <time_frame>Week 15</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Descending Pain Modulation From Baseline to End of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</title>
        <time_frame>Week 0 - Week 15</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Descending Pain Modulation From Baseline to Week 6 of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Descending Pain Modulation From Baseline to Week 9 of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</title>
        <time_frame>Week 9</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Descending Pain Modulation From Baseline to Week 15 of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)</title>
        <time_frame>Week 15</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Activation Patterns During N-back Procedure From Baseline to End of Treatment.</title>
        <time_frame>Week 0</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Activation Patterns During N-back Procedure From Baseline to Week 6 of Treatment.</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Activation Patterns During N-back Procedure From Baseline to Week 9 of Treatment.</title>
        <time_frame>Week 9</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in fMRI Activation Patterns During N-back Procedure From Baseline to Week 15 of Treatment.</title>
        <time_frame>Week 15</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Milnacipran</title>
          <description>Milnacipran was given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo was given orally twice daily in tablet form at different times during the course of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Herniated Disc</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Increased Blood Pressure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Sensitive to Light</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sore Eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Food Poisioning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Raw Tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cough/Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Unable to Void</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leg Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Distrubance in Attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Emotional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Clauw, MD</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-998-6901</phone>
      <email>dclauw@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
